Yanlei Dong

Yanlei Dong

Auto-generated profile, based on publicly available information

Yanlei Dong

Department of Immunology and Shandong Key Laboratory of Infection and Immunity, School of Basic Medical Sciences, Cheeloo College of Medicine Shandong University Jinan China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2025 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
ZMZelong Ma
Zelong Ma
YWYingyue Wang
Yingyue Wang
YDYanlei Dong
Yanlei Dong
HYHong Yuan
Hong Yuan
RYRuoxuan Yang
Ruoxuan Yang
YSYongyu Shi
Yongyu Shi
Introduction: Understanding the negative regulatory mechanisms of immune cell functions is essential for developing effective tumor immunotherapy strategies. Macrophages play a crucial role in antitumor immunity; however, the mechanisms that negatively regulate their antitumor functions remain incompletely understood. TIPE2 is known to be a critical regulator of various immune cells, but its role as a negative regulator of macrophage antitumor functions has not yet been established. Objectives: This study aims to investigate whether TIPE2 negatively regulates the antitumor functions of macrophages and to elucidate the mechanisms involved. Methods: We used a mouse model of hepatic tumor metastasis and a subcutaneous tumor model to evaluate the impact of TIPE2 on macrophage antitumor functions. In vitro experiments, including fluorescence microscopy and flow cytometry, were conducted to assess whether the TIPE2 deficiency enhances the phagocytic activity of macrophages against tumor cells. Additionally, we employed co-immunoprecipitation assays along with spleen tyrosine kinase (SYK) and Ras-related C3 botulinum toxin substrate 1 (RAC1) signaling blockade assays to investigate the molecular mechanisms through which TIPE2 exerts its negative regulatory effects. Results: Our findings indicate that TIPE2 gene loss in myeloid cells inhibits hepatic tumor metastasis, which is dependent on macrophages in the liver. Furthermore, macrophages lacking TIPE2 demonstrated enhanced tumor growth inhibition in subcutaneous tumor models. In vitro, these macrophages exhibited increased phagocytic activity against tumor cells. Mechanistically, TIPE2 negatively regulates the activation of SYK and RAC1, thereby modulating the phagocytic capabilities of macrophages. Conclusion: TIPE2 represents a negative regulatory mechanism for macrophage phagocytosis against tumor cells. In the future, TIPE2 may serve as a promising target to enhance the efficacy of tumor immunotherapy strategies based on macrophages.

7 October 2026 in Cancer Science
Verified
Journal Article
Open access
PDF file
YDYanlei Dong
Yanlei Dong
JYJing Yi
Jing Yi
RYRuoxuan Yang
Ruoxuan Yang
YWYingyue Wang
Yingyue Wang
ZMZelong Ma
Zelong Ma
YSYongyu Shi
Yongyu Shi
Immune checkpoint blockade (ICB) has demonstrated efficacy in clinical cancer therapy; however, a significant proportion of cancer patients do not respond to ICB. One contributing factor to this lack of response is the impairment of IFN‐γ signaling within cancer cells. A20 acts as a negative regulator of IFN‐γ signaling. Our study aimed to investigate the mechanism by which A20 exerts its negative regulatory effect on IFN‐γ signaling in hepatocellular carcinoma (HCC) cells. Bioinformatic analysis revealed that A20 expression in HCC cell lines is inversely associated with the activation of IFN‐γ signaling. Functional loss and gain experiments demonstrated that A20 inhibits IFN‐γ signaling in HCC cells. The interaction between A20 and STAT1 was assessed using Co‐Immunoprecipitation (Co‐IP) assays and bimolecular fluorescence complementation (BioFC) assays. Our results also indicated that A20 suppresses the expression of downstream molecules involved in IFN‐γ signaling, such as CXCL9, CXCL10, and HLA‐ABC, in HCC cells. Additionally, enforced expression of A20 in HCC cells inhibited anti‐tumor immunity in a mouse model of HCC. Bioinformatic analysis suggests that A20 may negatively regulate IFN‐γ signaling in HCC cells from human HCC cohorts. Collectively, our study uncovers a novel mechanism whereby A20 inhibits IFN‐γ signaling in HCC cells through direct binding with STAT1. These findings enhance our understanding of the regulatory mechanisms of IFN‐γ signaling in cancer cells and provide insights for designing strategies to enhance the effectiveness of ICB therapy.